View More Recent Stories
-
Insmed (INSM) Misses Q3 EPS by 7c ; Offers Guidance
-
Insmed (INSM) PT Raised to $100 at Truist Securities
-
TD Cowen Reiterates Buy Rating on Insmed (INSM)
-
Insmed (INSM): New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results
-
Insmed (INSM) option IV flat amid wide 2024 price movement
-
Stifel Reiterates Buy Rating on Insmed (INSM)
-
Goldman Adjusts Monthly US Directors Cut Conviction List
-
H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)
-
Insmed (INSM) PT Raised to $92 at Mizuho, 'continue to favor it as our top longer-term idea'
-
Insmed (INSM) PT Raised to $98 at TD Cowen
-
Insmed (INSM) Misses Q2 EPS by 70c ; Offers Guidance
-
RBC's biotech survey shows investors more bearish vs. last time
-
2Q24 U.S. biotech earnings preview
-
Mizuho Reiterates Outperform Rating on Insmed (INSM)
-
TD Cowen Reiterates Buy Rating on Insmed (INSM)
-
H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)
-
Insmed (INSM) PT Raised to $88 at Truist Securities
-
Insmed (INSM) Redeems $225M of Notes
-
Insmed (INSM) PT Raised to $90 at Barclays
-
Insmed (INSM) PT Raised to $75 at Evercore ISI
-
These stocks are Wells Fargo's 14 high-conviction ideas for Q2

